Page last updated: 2024-10-24

regulation of matrix metallopeptidase secretion

Definition

Target type: biologicalprocess

Any process that modulates the frequency, rate or extent of matrix metallopeptidase secretion. [GO_REF:0000058, GOC:TermGenie, PMID:8679543]

The regulation of matrix metallopeptidase (MMP) secretion is a complex process involving multiple levels of control, ensuring precise and timely release of these enzymes for tissue remodeling, development, and wound healing. Here's a detailed breakdown:

**1. Transcriptional Regulation:**
- **Transcription factors:** MMP genes are regulated by various transcription factors, including AP-1, NF-κB, and SP-1, which respond to various stimuli, such as cytokines (TNF-α, IL-1β), growth factors (TGF-β, EGF), and mechanical stress.
- **MicroRNAs:** Small non-coding RNAs (miRNAs) play a role in regulating MMP expression. Some miRNAs inhibit MMP expression, while others enhance it, contributing to the fine-tuning of MMP production.

**2. Post-transcriptional Regulation:**
- **mRNA stability:** MMP mRNA stability is influenced by factors like AU-rich elements in their 3' untranslated regions (UTRs), which are targeted by RNA-binding proteins that regulate mRNA decay.
- **mRNA splicing:** Alternative splicing can generate multiple MMP isoforms with distinct properties, potentially influencing their secretion and activity.

**3. Translation and Protein Folding:**
- **Ribosome binding:** The efficiency of ribosome binding to MMP mRNA can impact protein synthesis rates.
- **Chaperones:** Proper folding of MMP proteins is crucial for their activity and secretion. Chaperones like Hsp90 assist in folding and prevent misfolding, ensuring that functional MMPs are produced.

**4. Post-translational Modifications:**
- **Glycosylation:** Some MMPs undergo glycosylation, which can influence their stability, secretion, and interactions with other molecules.
- **Propeptide Processing:** MMPs are synthesized as inactive zymogens with a propeptide domain that blocks their active site. Proteolytic cleavage by specific enzymes (e.g., plasmin, other MMPs) removes the propeptide, activating the MMP.

**5. Trafficking and Secretion:**
- **Golgi Apparatus:** MMPs are transported through the Golgi apparatus where they undergo further modifications and sorting.
- **Secretory Vesicles:** MMPs are packaged into secretory vesicles, which bud off from the Golgi and migrate towards the plasma membrane.
- **Exocytosis:** Fusion of secretory vesicles with the plasma membrane releases MMPs into the extracellular matrix (ECM).

**6. Extracellular Regulation:**
- **Tissue inhibitors of metalloproteinases (TIMPs):** TIMPs are natural inhibitors of MMPs, binding to their active site and blocking their activity. The balance between MMPs and TIMPs is crucial for maintaining ECM integrity.
- **ECM interactions:** MMPs can bind to ECM components, influencing their localization and activity.
- **Other Proteases:** MMP activity can be regulated by other proteases, such as plasmin and thrombin, which can activate or inactivate specific MMPs.

**In summary, the regulation of MMP secretion is a multi-faceted process involving numerous molecular mechanisms. This ensures that MMPs are produced and released in a controlled manner, contributing to normal physiological processes and preventing uncontrolled degradation of the ECM.**'
"

Proteins (1)

ProteinDefinitionTaxonomy
Solute carrier family 12 member 2A solute carrier family 12 member 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P55011]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
bumetanideamino acid;
benzoic acids;
sulfonamide
diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
n-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamideN-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide: a KCC2 cotransporter antagonistpyridazines;
ring assembly